March 20, 2020 / 9:44 PM / 11 days ago

BRIEF-Liminal Biosciences Q4 Loss Per Share $0.62

March 20 (Reuters) - Liminal BioSciences Inc:

* LIMINAL BIOSCIENCES REPORTS FOURTH QUARTER AND 2019 YEAR END RESULTS

* LIMINAL BIOSCIENCES - REVENUES WERE $1.1 MILLION FOR Q4 2019, AS COMPARED TO $3.4 MILLION FOR Q4 2018

* LIMINAL BIOSCIENCES - NET LOSS ATTRIBUTABLE TO CO’S SHAREHOLDERS ON BASIC AND DILUTED PER SHARE BASIS WAS $0.62 FOR Q4 2019

* LIMINAL BIOSCIENCES - ANTICIPATED RESUBMISSION OF BLA WITH FDA FOR RYPLAZIMFOR TREATMENT OF CONGENITAL PLASMINOGEN DEFICIENCY, IN H1 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below